Quality of Life and Preference of COPD Patients After Switching From Tiotropium Monotherapy (Spiriva, Handihaler) to Dual Therapy With Tiotropium Bromide Plus Olodaterol (Spiolto, Respimat) Under Real Life Conditions in Greece (ELLACTO II Study)
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms ELLACTO II Study
- Sponsors Boehringer Ingelheim
- 08 Mar 2022 Status changed from active, no longer recruiting to completed.
- 03 Dec 2021 Status changed from recruiting to active, no longer recruiting.
- 17 Nov 2021 Planned End Date changed from 16 Feb 2022 to 2 Mar 2022.